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Abstract 
The presence of internal tandem duplications (ITDs) in the FLT3 receptor tyrosine kinase gene 
have long been known to confer a poor prognosis to acute myeloid leukemia (AML) patients.  
Now, specific structural features of the ITD are also suggested to alter patient outcome, 
including sensitivity to targeted therapies, prompting their evaluation in therapeutic algorithms. 
(54 words) 
Commentary 
In this issue of Clinical Cancer Research, Schwartz and colleagues show that structural 
features of FLT3-internal tandem duplications (ITDs) mutations, a highly recurrent mutation in 
acute myeloid leukemia (AML), influence patient responses and overall outcome following 
both standard cytotoxic chemotherapy and targeted FLT3 inhibitor therapy(1).  
AML is a genetically heterogeneous disease and several subtypes, characterized by different 
biological and prognostic features, have been described based on their mutational patterns 
and the presence of gross chromosomal alterations (2). Mutations affecting genes involved in 
signaling pathways are amongst the most frequently found in AML. In particular, mutations in 
the type-III receptor tyrosine kinase (TK) FLT3 are present in about 30% of AML patients. 
FLT3 mutations are mostly secondary to an internal tandem duplication (FLT3ITD) of the 
juxtamembrane domain which abrogates its negative regulatory function, resulting in 
constitutive activation of the receptor’s TK activity, and predict for an increased relapse rate 
following standard therapies and a poor prognosis(3).  
FLT3ITD mutations activate survival and proliferative signaling pathways, including 
phosphatidyl-inositol3-kinase (PI3K)/AKT, mitogen-activated protein kinase/extracellular 
signal-regulated kinase (MAPK/ERK), and signal transducer and activator of transcription 5 
(STAT5) thus explaining the hyperproliferative and aggressive phenotype of AML carrying 
these mutations. Quantification of variant allele frequency in patient DNA samples, genetic 
assessment at diagnosis and relapse and studies in animal models have respectively shown 
that FLT3ITD occur later in leukemia evolution and are not sufficient to produce an AML 
phenotype without collaborating mutations. Nevertheless, preclinical studies demonstrate that 
AML cells are oncogenically addicted to FLT3ITD thus suggesting its role as a therapeutic 
target(4). This has been also confirmed by the results of several recent phase 2 and 3 clinical 
trials that have demonstrated a survival benefit for patients treated with FLT3 TK inhibitors 
(TKI)(3). However, despite our improved understanding of the role played by FLT3ITD 
mutations in AML and the rational design of targeted inhibitors of their TK activity, the overall 
outcome of AML patients carrying FLT3ITD mutations remains poor and somewhat variable, 
with average overall response rates of less than 50% even following treatment with targeted 
FLT3 TKI. Several mechanisms have been shown to alter responses to FLT3 TKI including 
mutations in the FLT3 TK domain, cellular adaptive responses and disease features inherent 
to individual patients, such as FLT3ITD mutational burden and the presence of co-occuring 
mutations(2-4).   
The manuscript from Schwartz et al. provides a novel tool to further classify patients response 
to both standard cytotoxic and novel FLT3 TKI therapies based on the ITD structural features 
of FLT3ITD mutations. The authors developed a novel, publicly available, bioinformatic 
algorithm (HeatITup) which is able to detect the presence of FLT3ITD mutations from DNA next-
generation sequencing data from AML patients at diagnosis with better accuracy than other 
commonly used algorithms, validating their findings using both sequencing data from their own 
independent patient cohort and the TCGA AML dataset. Moreover, they show that HeatITup 
is capable of defining in fine details the structural features of ITD mutations in each patient. 
These include not only length of the duplicated section but also nucleotide composition 
including spacer regions and exogenous sequence within the insertion, as well as potentially 
relevant point mutations within the ITDs.  Using HeatITup, the authors then divide FLT3ITD 
mutations into "typical" or "atypical" subtypes, based respectively on the absence or the 
presence of nucleotides exogenous to the wildtype FLT3 locus within the mutated region. 
Interestingly, they demonstrate that typical and atypical mutations tend to cluster within each 
patient, i.e. patient harbouring multiple ITD clones tend to have mostly either typical or atypical 
clones. This suggests that these 2 types of mutations might represent different biological 
entities and/or represent the consequences of different mutational exposures or processes. 
Partially supporting this notion, they then show that patient carrying atypical FLT3ITD mutations 
have lower survival rates when treated with both standard cytotoxic chemotherapy and FLT3 
TKI therapy, within both their patient cohort and validated in the TCGA cohort.  
Although FLT3ITD allele burden, reflective of the size of the FLT3-mutated clone and or uni-
parental disomy for chromosome 13q, has been implicated in the prognosis of patients treated 
with standard chemotherapy, the role of duplication length is less well understood as there 
have been conflicting reports regarding a link between overall survival and ITD length(5). The 
work by Schwartz and colleagues adds to our knowledge on the role of structural features of 
FLT3ITD mutations by showing that, beside length, other structural features of the ITDs may 
have an impact on patient outcome and that this might also hold true in the era of novel 
targeted therapy with FLT3 TKI. These findings will need to be validated in other independent 
datasets and the software the authors have developed will provide an accessible 
computational algorithm to enable these studies. If confirmed in larger studies, these results 
will also support the concept that characterization of FLT3ITD complexity, beside their 
detection, should be used to inform clinical decision-making and in the therapeutic algorithm 
for AML patients carrying FLT3ITD mutations.  
Some of the observations from the author’s work, if further confirmed, also raise interesting 
biological questions that, if confirmed, should be specifically addressed in experimental 
models of FLT3ITD leukemia. In particular, it would be interesting to understand how the 2 
classes of ITD mutations confer a different response/sensitivity to treatment. Important 
questions could include; Does the type of ITD alter the native activity of mutated FLT3 and are 
typical and atypical ITDs different in the intensity of their signalling and FLT3 activity? 
Alternatively, as the 2 classes predict response to both standard cytotoxic and FLT3 TKI 
therapy, is the differential sensitivity to therapy independent of FLT3 activity and reflect other 
processes such as increased/altered mutagenesis? Moreover, given that typical and atypical 
mutations tend to cluster within each patient, do these 2 types of mutations represent the 
consequences of different mutational exposures or processes? Interestingly, the author’s data 
show that the pattern and number of co-occuring mutations is not different between the 2 
classes of ITDs within their cohort, which seems to suggest similar rates of mutation. 
Nevertheless, further validation in bigger cohorts and a more in depth analysis of their biology 
might help to clarify if patients carrying each subtype of mutations show differential response 
to DNA damage and highlight the mechanisms behind their almost complete mutual 
exclusivity.  
In conclusion, the manuscript by Schwartz represents another incremental step towards 
implementing precision medicine for AML patients carrying FLT3ITD mutations. Their HeatITup 
algorithm will be a valuable, easy-to-use and publicly available tool to stratify patients 
according to the structural features of their ITD mutations. It is also conceivable that this 
algorithm could be used to generically detect and classify ITD mutations reported in various 
genes for other subtypes of leukemia and solid cancers. Future studies will help to further 
validate these findings, clarify the features modulating the response to FLT3 TKI and standard 
chemotherapy in AML patients and understand their underlying biological mechanisms.  
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Figure Legend 
Sequencing data from AML patients DNA can be analysed using the authors HeatITup 
algorithm to detect FLT3ITD mutations and classify them, based on the ITD structural features, 
in typical or atypical. This classification could then be used to inform patient prognosis and 
design more effective therapeutic algorithm for AML patients carrying FLT3ITD mutations. 
 
 
 

